LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Search

Guardant Health Inc

Geschlossen

BrancheGesundheitswesen

99.91 3.74

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

94.86

Max

100.62

Schlüsselkennzahlen

By Trading Economics

Einkommen

-36M

-128M

Verkäufe

16M

281M

EPS

-0.5

Gewinnspanne

-45.684

Angestellte

2,490

EBITDA

-37M

-119M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+33.26% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Juli 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.5B

12B

Vorheriger Eröffnungskurs

96.17

Vorheriger Schlusskurs

99.91

Nachrichtenstimmung

By Acuity

50%

50%

175 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Mai 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11. Mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11. Mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11. Mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11. Mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11. Mai 2026, 22:32 UTC

Ergebnisse

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11. Mai 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11. Mai 2026, 21:49 UTC

Ergebnisse

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11. Mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11. Mai 2026, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11. Mai 2026, 21:23 UTC

Akquisitionen, Fusionen, Übernahmen

CSG Systems Sale to NEC Gets CFIUS Clearance

11. Mai 2026, 21:12 UTC

Ergebnisse

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11. Mai 2026, 21:12 UTC

Ergebnisse

Ovintiv 1Q Loss/Shr $2.35 >OVV

11. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11. Mai 2026, 20:44 UTC

Ergebnisse

Steris: Board Approves New $1B Shr Repurchase Program >STE

11. Mai 2026, 20:43 UTC

Ergebnisse

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11. Mai 2026, 20:32 UTC

Ergebnisse

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11. Mai 2026, 20:32 UTC

Ergebnisse

CleanSpark 2Q Rev $136.4M >CLSK

11. Mai 2026, 20:30 UTC

Ergebnisse

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Cont Ops EPS $2.24 >STE

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Rev $1.6B >STE

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Adj EPS $2.83 >STE

11. Mai 2026, 20:22 UTC

Heiße Aktien

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11. Mai 2026, 19:37 UTC

Ergebnisse

More Bad News at KKR's Private Credit Fund -- Barrons.com

11. Mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

33.26% Vorteil

12-Monats-Prognose

Durchschnitt 128.88 USD  33.26%

Hoch 175 USD

Tief 92 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

18

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

175 / 346 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat